MDR1 C3435T Polymorphisms Correlate With Cyclosporine Levels in De Novo Renal Recipients

Transplantation Proceedings

Volumn 38, Issue 9, 2006, Pages 2847-2849

  Foote, C J ^a   Greer, W ^a   Kiberd, B A ^a   Fraser, A ^a   Lawen, J ^a   Nashan, B ^a   Belitsky, P ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GENE PRODUCT; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE SODIUM SUCCINATE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA POLYMORPHISM; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE;

ADULT; AREA UNDER CURVE; BODY WEIGHT; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 33750935453     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.08.120     Document Type: Article

References (26)

1. Kahan B., Welsh M., and Schoenberg L. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 62 (1996) 599
2. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Transplantation 72 (2001) 1024
3. International Neoral Renal Transplantation Study Group. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2 (2002) 148
4. Clase C., Mahalati K., and Kiberd B. Adequate early cyclosporine exposure is critical to renal allograft rejection: patients monitored by absorption profiling. Am J Transplant 2 (2002) 789
5. Eichelbaum M., Fromm M.F., and Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 26 (2004) 180
6. Fricker G., Drewe J., and Huwyler J. Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol 118 (1996) 1841
7. Fromm M. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 54 (2002) 1295
8. Tanabe M., Leiri I., and Nagata N. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR1) gene. J Pharmacol Exp Ther 297 (2001) 1137
9. Hoffmeyer S., Burk O., and von Richter O. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97 (2000) 3473
10. Kim R., Leake B., and Choo E. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70 (2001) 189
11. Nakamura T., Sakaeda M., and Horinouchi M. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 71 (2002) 297
12. Johne A., Kopke K., and Gerloff T. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 72 (2002) 584
13. Mai I., Stormer E., and Goldammer M. MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. J Clin Pharmacol 43 (2003) 1101
14. von Ahsen N., Richter M., and Grupp C. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporine A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 47 (2001) 1048
15. Haufroid V., Mourad M., and Van Kerckhove V. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14 (2004) 147
16. Min D., and Ellingrod V. C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 24 (2002) 400
17. Keown P.A., Kiberd B., and Balshaw R. An economic model of 2-hour post-dose ciclosporin monitoring in renal transplantation. Pharmacoeconomics 22 (2004) 621
18. Clase C.M., Mahalati K., and Kiberd B.A. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am J Transplant 2 (2002) 789
19. Mahalati K., Belitsky P., and Sketris I. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 68 (1999) 55
20. 2 hour monitoring after renal transplantation. Int J Clin Pharmacol Ther 41 (2003) 477
21. Kuzuya T., Kobayashi T., and Moriyama N. Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. Transplantation 76 (2004) 865
22. Anglicheau D., Thervet E., and Etienne I. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 75 (2004) 422
23. List A., Kopecky K., and Appelbaum F. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98 (2001) 3212
24. Lum B., Kaubisch S., and Fisher G. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance. Cancer Chemother Pharmacol 45 (2000) 305
25. del Moral R., Andujar M., and Ramirez C. Chronic cyclosporin A nephrotoxicity, P-glycoprotein overexpression, and relationships with intrarenal angiotensin II deposits. Am J Pathol 151 (1997) 1705
26. Grude P., Boleslawski E., and Conti F. MDR1 gene expression in peripheral blood mononuclear cells after liver transplantation. Transplantation 73 (2002) 1824